Strategic Collaboration with FMI Announced

Our realization of the value of comprehensive molecular profiling resulted in a broad, strategic partnership with FMI, the leader in the field. This collaboration, which recently culminated in a full acquisition, has led to the development of novel platforms, development of the Foundation One CDx panel as a multi-drug, universal companion diagnostic platform and the ability to query the Foundation Medicine database to inform further drug development.